Trial Profile
A Double-blind, Randomized-Withdrawal, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Human Plasma-Derived C1-esterase Inhibitor as Add-on to Standard of Care for the Treatment of Refractory Antibody Mediated Rejection in Adult Renal Transplant Recipients
Status:
Discontinued
Phase of Trial:
Phase III
Latest Information Update: 30 Jan 2023
Price :
$35
*
At a glance
- Drugs Complement C1 inhibitor protein (Primary) ; Complement C1 inhibitor protein (Primary)
- Indications Renal transplant rejection
- Focus Therapeutic Use
- Sponsors CSL Behring
- 22 Jan 2021 Status changed from active, no longer recruiting to discontinued, due to a business decision and not for safety reasons.
- 13 Jan 2021 This trial has been Discontinued in Spain, according to European Clinical Trials Database record.
- 12 Jan 2021 Planned End Date changed from 15 Jan 2026 to 20 Jan 2021.